Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bad Dürrnberg – page 19

328 clinical trials in Bad Dürrnberg, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bad Dürrnberg at a glance
328
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

328 trials in Bad Dürrnberg

Open in trial search

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Prostate cancer

Not recruiting

Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Medivation Inc.

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Prostate cancer

Not recruiting

Study of Florastamin (18F) PET/CT Imaging for Detection of Significant Prostate Cancer in Patients with Elevated PSA Levels and Unclear MRI Results

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(9S,13S)-1-(1-(2-(2-(2-[18F]Fluoroethoxy)Ethoxy)Ethyl)-1H-1,2,3-Triazol-4-Yl)-3,11-Dioxo-2,4,10,12-Tetraazapentadecane-9,13,15-Tricarboxylicacid
  • Sponsor:Curium Austria GmbH

Uveitis+1

Not recruiting

Study on Izokibep for Patients with Non-infectious Uveitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Izokibep
  • Sponsor:Acelyrin Inc.

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AMG 193
  • Sponsor:Amgen Inc.

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Astrazeneca AB

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AB-1002
  • Sponsor:Askbio Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bad Dürrnberg

What the registry says about research in the country

01 Women's Health Research

Investigating innovative treatments for menopausal symptoms, specifically focusing on sleep-related challenges that affect women's quality of life.

  • Sleep Disorders
  • Menopausal Health
  • Treatment Evaluation

Current research explores the effectiveness of new therapeutic approaches in managing sleep disturbances associated with menopause, aiming to provide better treatment options for women experiencing these symptoms.

02 Sleep Medicine Studies

Advanced clinical research utilizing polysomnography to evaluate treatment efficacy for sleep-related disorders in menopausal women.

  • Sleep Pattern Analysis
  • Treatment Response
  • Clinical Assessment

Studies employ sophisticated monitoring techniques to understand how novel treatments may improve sleep quality during the menopausal transition.

03 Therapeutic Development

Evaluating the safety and effectiveness of elinzanetant as a potential treatment option for managing menopause-related sleep disruptions.

  • Safety Assessment
  • Efficacy Studies
  • Treatment Innovation

Research focuses on developing targeted therapies to address specific symptoms associated with menopausal transition.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.